Article info
PDFEpidemiology
Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis
- Correspondence to Dr Stephan Blüml, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna 1090, Austria; stephan.blueml{at}meduniwien.ac.at
Citation
Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis
Publication history
- Received August 13, 2021
- Accepted November 5, 2021
- First published November 29, 2021.
Online issue publication
May 04, 2023
Article Versions
- Previous version (13 April 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage